Characteristics |
| Number (%) |
Gender | Male | 100 (46) |
Female | 116 (54) | |
Age | <40 years | 24 (11) |
Between 40 and 60 years | 76 (35) | |
Between 60 and 80 years | 108 (50) | |
>80 years | 8 (4%) | |
TKI studied | Imatinib | 69 (32) |
Sunitinib | 69 (32) | |
Sorafenib | 22 (10) | |
Lapatinib | 22 (10) | |
Pazopanib | 15 (7) | |
Afatinib | 11 (5) | |
Erlotinib | 5 (2.5) | |
Regorafenib | 2 (1) | |
Axitinib | 1 (0.5) | |
TKI indications | Kidney cancer | 78 (36) |
GIST | 71 (33) | |
Breast cancer | 22 (10) | |
Lung cancer | 16 (7.5) | |
thyroidcarcinoma | 12 (5.5) | |
HCC | 9 (4.5) | |
Others | 8 (4) |